Erythropoietin: Physiology and molecular mechanisms

Heart Failure Reviews

Volumn 13, Issue 4, 2008, Pages 405-414

  Foley, Robert N ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Erythropoietin; Hypoxia induciblefactor 1; Physiology; Receptor; Treatment

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLOPEPTIDE; DIMER; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FELODIPINE; HEMOGLOBIN; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; MEMBRANE RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN; OXYGENASE INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SYNTHETIC PEPTIDE;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CATALYSIS; CELL TYPE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG TARGETING; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION; GENE THERAPY; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN PHOSPHORYLATION; PURE RED CELL ANEMIA; QUALITY OF LIFE; RECEPTOR BINDING; RISK BENEFIT ANALYSIS; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ERYTHROCYTES; ERYTHROPOIETIN; HEMATINICS; HUMANS; HYPERTENSION; HYPOXIA-INDUCIBLE FACTOR 1; RECEPTORS, ERYTHROPOIETIN;

EID: 43749102443     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9083-0     Document Type: Article

References (97)

1. Carnot P (1906) Sur l'activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci (Paris) 143:384-386
2. Reissmann KR (1959) Studies on the mechanism of erythropoietin stimulation in parabiotic rats during hypoxia. Blood 5:347-380
3. Jacobson LO (1957) Role of the kidney in erythropoiesis. Nature 179:633
4. Miyake T (1977) Purification of human erythropoietin. J Biol Chem 252:5558-5564
5. Lin FK et al (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 92:7580-7584
6. Jacobs K (1985) Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 313:806-810
7. Fisher JW (1997) Erythropoietin: Physiologic and pharmacologic aspects. Proc Soc Exp Biol 16:358-369
8. Adamson JW (1988) Erythropoietin: In vitro and in vivo studies of the regulation of erythropoiesis. Schweiz Med Wochenschr 118:1501-1506
9. Jelkmann W (1992) Erythropoietin: Structure, control of production, and function. Physiol Rev 72:449-489
10. Manolis AS (2005) Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 5:355-375
11. Wang GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90:4304-4308
12. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 107:1-3
13. Zhu H (2001) Signal transduction: How do cells sense oxygen? Science 292:449-451
14. Prchal JT (2003) Delivery on demand a new era of gene therapy? N Engl J Med 348:1282-1283
15. Ang SO (2002) Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32:614-621
16. Rossert J (2005) Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol Dial Transplant 20:1025-1028
17. Lacombe C (1999) The molecular biology of erythropoietin. Nephrol Dial Transplant 14 Suppl 2:22-28
18. Ratajczak J (2001) Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 115:195-204
19. Digicaylioglu M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92:3717-3720
20. Juul SE (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249
21. Anagnostou A et al (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91:3974-3978
22. Silva M (1999) Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274:22165-22169
23. Kashii Y (2000) A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96:941-949
24. Digicaylioglu M (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647
25. Yang CW (2003) Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17:1754-1755
26. Wu H (1995) Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83:59-67
27. Lin CS (1996) Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 10:154-164
28. Vaziri ND (2001) Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10:633-637
29. Vaziri ND (1996) Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271:E113-E122
30. Vaziri ND et al (1995) In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269:F838-F845
31. Marrero MB (1998) Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int 53:1259-1268
32. Miller BA (1994) Mechanisms of erythropoietin signal transduction: involvement of calcium channels. Proc Soc Exp Biol Med 206:263-267
33. Lebel M (1998) Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens 20:939-951
34. Rodrigue ME (2003) Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol 41:388-395
35. Eggena P (1991) Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261:E642-E646
36. Barrett JD (1998) Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 6:1749-1757
37. Lebel M (2006) Antihypertensive and renal protective effects of Renin-Angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 19:1286-1292
38. Casadevall N (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475
39. Bennett CL (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403-1408
40. Boven K (2005) Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: Solving the mystery. Nephrol Dial Transplant 20 Suppl 3:iIi33-40
41. Boven K (2006) The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67:2346-2353
42. Macdougall IC (2006) Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368(9539):947-953
43. Egrie JC (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 Suppl 1:3-10
44. Macdougall IC (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395
45. Nissenson AR (2002) Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110-118
46. Vanrenterghem Y (2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175
47. Jadoul M (2004) Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898-903
48. Macdougall IC (2006) CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4:436-440
49. de Francisco AL (2006) Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: A randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 60:1687-1696
50. Kochendoerfer GG (2003) Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299(5608):884-887
51. Sytkowski AJ (1999) An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274:24773-24778
52. Wrighton NC (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274):458-464
53. Stead RB (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830-1834
54. Qureshi SA (1999) Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96:12156-12161
55. Schofield CJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343-354
56. Safran M (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA 103:105-110
57. Schwenter F (2004) Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 15:669-680
58. Fattori E (2005) Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 7:228-236
59. Rivera VM (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105:1424-1430
60. Lippin Y (2005) Human erythropoietin gene therapy for patients with chronic renal failure. Blood 106:2280-2286
61. Binley K (2002) Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 100:2406-2413
62. Eschbach JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78
63. Eschbach JW (1989) Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163
64. Foley RN, Ritz E (2005) Cardiovascular risk factors. In: Davsion AM et al (eds) Oxford textbook of clinical nephrology. Oxford, United Kingdom
65. Besarab A (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590
66. Furuland H (2003) A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353-361
67. Foley RN (2000) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335
68. Parfrey PS (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180-2189
69. Levin A (2005) Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46:799-811
70. Suzuki M (1989) Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol 76:179-192
71. Roger SD (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15:148-156
72. Nissenson AR (1995) Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5:1517-1529
73. Bahlmann J (1991) Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol 88:90-106
74. Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300:573-578
75. Roth D (1994) Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784
76. Revicki DA (1995) Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554
77. Kuriyama S (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185
78. Sikole A (1993) Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17:977-984
79. Weiss LG (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: Results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15:2014-2019
80. Lim VS (1989) Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110:108-114
81. Kleinman KS (1989) The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14:486-495
82. McMahon LP (1999) Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187
83. McMahon LP (1992) Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 7:1199-1206
84. Watson AJ (1990) Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 89:432-435
85. Morris KP (1993) Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. Arch Dis Child 68:644-648
86. Drueke TB (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071-2084
87. Singh AK (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-2098
88. Rossert J (2006) Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47:738-750
89. Macdougall IC (2007) Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 22:784-793
90. Phrommintikul A (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369(9559):381-388
91. Foley RN et al (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61
92. Ma JZ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619
93. Hansson L (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118):1755-1762
94. Locatelli F (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 Suppl 2:iI1-47
95. KDOQI (2006) National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47(5 Suppl 3):S11-145
96. KDOQI (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:471-530
97. http://www.fda.gov/cder/drug/infopage/RHE